Hlib Chabaniuk

Myriad Genetics unveils ultra-sensitive MRD testing focus at Tokyo oncology summit

Myriad Genetics unveils ultra-sensitive MRD testing focus at Tokyo oncology summit
Myriad Genetics pushes MRD frontier

Myriad Genetics is set to participate in the World Clinical Biomarkers & Companion Diagnostics Summit Japan, kicking off with a pre-conference Engager dedicated to advancements in precision oncology.

The company will spotlight the growing role of ultra-sensitive, tumor-informed minimal residual disease (MRD) testing at the event held at Hyatt Regency Tokyo on May 18. This reflects a broader push within the sector to develop more refined cancer detection and monitoring solutions. Industry stakeholders and research leaders gathered at the summit are expected to share further insights into future directions for precision diagnostic technologies.

Myriad Genetics recently confirmed its attendance at two additional healthcare conferences, further expanding its industry engagement earlier this year. The company also published its first quarter results for the period ended March 31, 2026, and maintained its full-year financial guidance for 2026. These moves reflect ongoing activity in both the operational and financial spheres for the firm.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.